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BACKGROUND AND PURPOSE
Adrenomedullin (AM) is a peptide hormone whose receptors are members of the class B GPCR family. They comprise a
heteromer between the GPCR, the calcitonin receptor-like receptor and one of the receptor activity-modifying proteins 1–3.
AM plays a significant role in angiogenesis and its antagonist fragment AM22–52 can inhibit blood vessel and tumour growth.
The mechanism by which AM interacts with its receptors is unknown.
EXPERIMENTAL APPROACH
We determined the AM22–52 binding epitope for the AM1 receptor extracellular domain using biophysical techniques,
heteronuclear magnetic resonance spectroscopy and alanine scanning.
KEY RESULTS
Chemical shift perturbation experiments located the main binding epitope for AM22–52 at the AM1 receptor to the C-terminal 8
amino acids. Isothermal titration calorimetry of AM22–52 alanine-substituted peptides indicated that Y52, G51 and I47 are
essential for AM1 receptor binding and that K46 and P49 and R44 have a smaller role to play. Characterization of these
peptides at the full-length AM receptors was assessed in Cos7 cells by cAMP assay. This confirmed the essential role of Y52,
G51 and I47 in binding to the AM1 receptor, with their substitution resulting in 100-fold reduction in antagonist potency
compared with AM22–52. R44A, K46A, S48A and P49A AM22–52 decreased antagonist potency by approximately 10-fold.
CONCLUSIONS AND IMPLICATIONS
This study localizes the main binding epitope of AM22–52 to its C-terminal amino acids and distinguishes essential residues
involved in this binding. This will inform the development of improved AM receptor antagonists.
Abbreviations
AM, adrenomedullin; Boc, tert-Butoxycarbonyl; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like
receptor; DMF, dimethylformamide; DoDt, 3,6-dioxa-1,8-octane-dithiol; ECD, extracellular domain; Fmoc,
9-fluorenylmethyloxycarbonyl; HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate;
RAMP, receptor activity-modifying protein; TFA, trifluoroacetic acid; TIPS, triisopropylsilane
Introduction
Class B GPCRs are important drug targets, with their natural
peptide ligands or mimetics being used to treat diseases,
including diabetes and osteoporosis (Archbold et al., 2011).
Structural insights into peptide binding to these receptors
gives guidance as to how the peptides could be modified and
further improved for therapeutic purposes. Some class B
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GPCRs require receptor activity-modifying proteins (RAMPs)
for high-affinity peptide interactions. The receptors for
adrenomedullin (AM) and the related peptides calcitonin
gene-related peptide (CGRP) and amylin belong to this cat-
egory. The AM receptors are heteromers of the calcitonin
receptor-like receptor (CLR) and RAMPs 2 or 3, which form
the AM1 and AM2 receptors respectively (Poyner et al., 2002).
CLR with RAMP1 makes the CGRP receptor but this also has
affinity for AM.
AM is a paracrine factor and is involved in the develop-
ment of the lymphatic and blood vasculature (Hinson et al.,
2000; Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008).
Embryonic lethality, thin blood vessel walls and significant
defects observed in the vascular systems of AM, CLR and
RAMP2 knock-out mice can be explained by abnormalities in
the blood and lymphatic vasculature (Caron and Smithies,
2001; Dackor et al., 2006; 2007; Fritz-Six et al., 2008;
Ichikawa-Shindo et al., 2008). Inhibition of AM activity by its
antagonist fragment AM22–52 can reduce vessel number and
impede tumour growth (Ishikawa et al., 2003). These data
indicate that angiogenesis is induced by AM through the
AM1 receptor, and that this receptor could be an attractive
target for diseases characterized by insufficient or excessive
angiogenesis.
There is as yet very little information on the structure–
function relationships of AM. In detergent micelles, AM
exhibits negligible helical structure, although NMR analysis
indicates that a helix is formed between residues 22 and 34, a
finding that is corroborated by circular dichroism (CD) data
(Robinson et al., 2009; Perez-Castells et al., 2012). Chimeras
of AM with related peptides indicated that its C-terminal 9
amino acids may be in proximity to RAMP3 in the AM2
receptor, but no similar data currently exist to indicate the
specific regions of AM involved in its binding to the AM1
receptor (Robinson et al., 2009).
Like other class B GPCRs, CLR is characterized by a large
N-terminal extracellular domain (ECD) and seven trans-
membrane helices connected by intra- and extracellular
loops and an intracellular C-terminal tail. Peptide binding
to class B GPCRs is widely accepted to follow the two-
domain model (Parthier et al., 2009). The C-terminus of
the peptide binds to the large ECD through hydrophobic
interactions, forming an a-helix. The receptor-activating
N-terminus of the peptide can then dock into its binding
pocket in the juxtamembrane region (the top of the TM and
adjoining region of the extracellular loops) of the receptor.
ECD crystal structures of CLR with RAMP1 and RAMP2 are
now available, which reveal that despite its requirement for
RAMP association, CLR shows high structural similarity to
class B GPCRs, which do not require RAMPs to function
(Grace et al., 2007; Parthier et al., 2007; Pioszak and
Xu, 2008; Underwood et al., 2010a,b; Drechsler et al.,
2011). Nevertheless, the CLR/RAMP structures do not have
peptide bound and there is clear evidence that RAMPs con-
tribute to peptide binding (Qi and Hay, 2010; Archbold
et al., 2011). Thus, the mode of binding of AM to its recep-
tors remains to be determined. In this study, we sought to
determine the regions of AM22–52 that are involved in
binding to the AM1 receptor with a view to designing ana-
logues of AM22–52 that exhibit increased affinity for the AM1
receptor.
Methods
Peptide synthesis
AM22–52 and its derivatives were synthesized using
9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide
synthesis methodologies on a Tribute peptide synthesizer
(Protein Technologies, Inc., Tucson, AZ, USA). The peptides
were assembled on a 0.1 mmol scale using Aminomethyl
ChemMatrix resin (PCAS Biomatrix Inc., Quebec, Canada)
derived with the Fmoc-RINK linker (GL-Biochem, Shanghai,
China) so as to afford a C-terminal amide on cleavage from
the resin.
Fmoc deprotections were carried out by twice treating the
resin with 3 mL of 20% piperidine (Sigma-Aldrich, St. Louis,
MO, USA) in dimethylformamide (DMF) (Scharlau, Gillman,
SA, Australia) for 5 min. For each coupling, 0.5 mmol of the
Na-Fmoc-amino acid was dissolved in 2 mL of 0.23 M 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluoro-
phosphate (HBTU) (Peptides International Inc., Louisville,
KY, USA) in DMF and added to the resin followed by 0.5 mL
of 2 M N-methylmorpholine (Sigma-Aldrich) in DMF, and
then allowing a reaction time of 40 min.
After its completion, the peptide was cleaved from the
resin with concomitant removal of side chain-protecting
groups by treatment with 10 mL of trifluoroacetic acid (TFA)/
3,6-dioxa-1,8-octane-dithiol (DoDT)/H2O/triisopropylsilane
(TIPS) (94:2.5:2.5:1 v/v) for 2 h at room temperature. After
filtering, the peptide was precipitated from the filtrate by
adding 40 mL of ice-cold ether and then pelleted by centrifu-
gation. The supernatant was discarded and the pellet was
washed well with chilled ether, air-dried, dissolved in water
(15 mL), and lyophilized and stored at -30°C in siliconized
microcentrifuge tubes.
AM22–52 labelled with 15N and 13C was also synthesized
using Fmoc solid-phase synthesis. Labelled Fmoc-protected
amino acids were purchased from Sigma-Aldrich and
from Cambridge Isotope Laboratories (Andover, MA, USA).
ChemMatrix aminomethyl resin was firstly derived with
the Fmoc-Rink linker by treatment with a mixture com-
posed of a 5-fold molar excess of the Fmoc-Rink acid,
5-fold molar excess of HBTU and 10-fold molar excess of
diisopropylamine in DMF (acid concentration of 0.2 M).
Synthesis of the peptide was carried out on a 0.025 mmol
scale using this resin and a Tribute peptide synthesizer
(Protein Technologies, Inc.). The iterative deprotection-
coupling procedure entailed firstly treatment of the
resin with 20% (v/v) solution of piperidine in DMF,
washing and then incubating with approximately 0.5 mL
of a solution comprising 5 equivalents of Fmoc-amino
acid (0.125 mmol), 5 equivalents of 2-(6-chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluoro-
phosphate and 10 equivalents of N-methylmorpholine in
DMF for 1 h. Upon completion of the synthesis, the final
Fmoc group was removed and the peptide was cleaved
from the resin over 2 h using 5 mL of a mixture of
TFA, DoDt, H2O and TIPS (94:2.5:2.5:1 v/v). The peptide
was precipitated by diluting the TFA solution with 8
volumes of chilled diethyl ether, collected as a pellet by
centrifugation, re-dissolved in 1:1 (v/v) acetonitrile/water
and lyophilized.
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Peptide purification and characterization
Unlabelled peptides were purified on a semi-preparative scale
by RP-HPLC using the Dionex UltiMate® 3000 Binary Semi-
preparative system (Thermo Scientific, Sunnyvale, CA, USA).
Samples were purified on a Gemini C-18 column (10 ¥
250 mm, 5 mm, 110 Å; Phenomenex, Torrance, CA, USA)
using 0.1% TFA/ultra-pure water as eluent A and 0.1% TFA/
acetonitrile as eluent B and generating a linear gradient of
0–30% B over 50 min at a flow rate of 5 mL·min-1. The puri-
fied material was lyophilized for 72–96 h and stored at -30°C
in siliconized microcentrifuge tubes.
The identity of the purified products was confirmed by
ion-spray MS on a Thermo Finnigan Surveyor MSQ Plus spec-
trometer (Thermo Electron Corporation, Waltham, MA,
USA). Analytical RP-HPLC was performed on a Gemini C-18
column (4.6 ¥ 250 mm, 5 mm, 110 Å; Phenomenex) on a
linear gradient of 0–50% buffer B over 60 min at a flow rate of
1 mL·min-1, with UV absorbance monitored at 210 nm. The
integration of the HPLC chromatograms at 210 nm indicated
a purity of at least 90%. Amino acid analyses were performed
by the Australian Proteome Analysis Facility Ltd. For assays,
peptides were dissolved in water to a concentration of 1 mM,
accounting for peptide content and stored as aliquots at
-30°C in siliconized microcentrifuge tubes.
Purification of labelled AM22–52 was carried out by
RP–HPLC, in which 1 mL aliquots of a 8 mg·mL-1 aqueous
solution of the peptide was loaded onto a Jupiter Proteo 4 mm
90 Å, 10 ¥ 250 mm column (Phenomenex) and eluted with a
gradient of 1–31% buffer B over 60 min. The resulting peptide
is referred to as 13C/15N-AM22–52.
Cell culture and transfection
Culture of Cos-7 cells was performed as previously described
(Bailey and Hay, 2006). Cells were cultured in DMEM supple-
mented with 8% heat inactivated FBS and 5% (v/v) penicillin/
streptomycin and kept in a 37°C humidified 95% air/5%CO2
incubator. Cells were seeded into 96 well plates at a density of
10 000 cells per well (determined using Countess Counter™;
Life Technologies, Carlsbad, CA, USA) 1 day prior to transfec-
tion. Cells were transiently transfected using polyethylen-
imine as described previously (Bailey and Hay, 2006) using
full-length HA-tagged CLR and full-length untagged RAMP1,
2 or 3 constructs. These combinations generated human
CGRP, AM1 and AM2 receptors respectively. This nomencla-
ture conforms to the British Journal of Pharmacology’s Guide
to Receptors and Channels (Alexander et al., 2011).
cAMP assays
cAMP assays were performed as previously described (Gingell
et al., 2010). On the day of the assay, cells were serum-
deprived in 50 mL per well DMEM containing 1 mM
3-isobutyl-1-methylxanthine and 0.1% BSA for 30 min. Full-
length human AM (American Peptide, Sunnyvale, CA, USA),
reconstituted to 1 mM in ultra-pure water, was diluted in the
same medium to give a final concentration range of 1 pM–
1 mM. This material was added (25 mL per well), in the
absence or presence of AM22–52 (25 mL per well), and incubated
at 37°C for 15 min. Forskolin (50 mM) (Tocris Bioscience,
Bristol, UK) was included as a positive control on each plate.
Pre-incubation with AM22–52 for up to 30 min did not affect
our antagonist potency estimates (data not shown). After
incubation, the contents of the wells were aspirated and
cAMP was extracted by adding 50 mL of lysis buffer as per the
AlphaScreen protocol (PerkinElmer, Boston, MA, USA). The
plates were gently shaken at room temperature for 15 min. A
cAMP standard curve was generated from the kit cAMP stand-
ard (AlphaScreen cAMP assay kit; PerkinElmer) in the range of
100 pM–2.6 mM, 10 mL per well and was added to a white
384-well opti-plate (PerkinElmer). Ten microliters of each cell
lysate was transferred to the plate. Five microliters of acceptor
beads (1:100 dilution in lysis buffer) was added to each well,
the plate was sealed and incubated in the dark for 30 min at
room temperature. Five microliters of the donor bead mix
(1:100 dilution of donor beads and biotinylated cAMP in the
lysis buffer) was added to all wells; the plate was resealed and
incubated in the dark for 6 h. The plates were read using an
Envision plate reader (AlphaScreen protocol; PerkinElmer).
The quantity of cAMP produced was determined from the raw
data using the cAMP standard curve. A comparison of AM22–52
(American Peptide) and in-house synthesized AM22–52 was
carried out to confirm that there was no difference between
these peptides (data not shown). 13C/15N-AM22–52 was also
compared and behaved equivalently to unlabelled peptide
(Table 2).
Data analysis and statistical procedures for
cAMP assay data
Data analysis, statistical interpretation, curve fitting and
graphing were undertaken using GraphPad Prism 5 (Graph-
Pad Software Inc., San Diego, CA, USA). The data from each
concentration–response curve were fitted to a sigmoidal
curve using a four-parameter logistic equation in order to
calculate the maximum response (Emax) and the log EC50
values, with a Hill slope of 1, after first comparing fits by
F-test. For calculation of antagonist potency values (pA2),
agonist concentration–response curves were fitted in the
absence or presence of antagonist and analysed by global
Schild analysis as previously described (Hay et al., 2005).
AM22–52 is a competitive antagonist (Hay et al., 2003); Schild
slopes were not significantly different to one and were there-
fore constrained to one to derive antagonist potency esti-
mates. Statistical analysis was carried out by one-way ANOVA
followed by Dunnett’s test, and the significance was accepted
at P < 0.05. Data are presented graphically as the mean of
normalized data; in each experiment, data were normalized
to the maximal AM response.
Recombinant protein expression
and purification
CLR (23–133) and RAMP2 (36–144) constructs were con-
structed as previously described (Koth et al., 2010) and
encoded an N-terminal hexahistidine tag and Tobacco Etch
Virus cleavage site on the RAMP2 construct. Expression in
Escherichia coli Rosetta 2 cells was carried out at 37°C with
induction at OD600 nm of 0.6 for 3 h at a final concentration
of isopropyl thiogalactopyranoside of 0.5 mM. Bacteria were
harvested by centrifugation and inclusion bodies isolated as
previously described (Koth et al., 2010). Twenty milligrams of
both CLR and RAMP2 inclusion bodies were added to 100 mL
of 8 M urea (pH 8.0) and co-refolded against refolding buffer
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[20 mM Tris–HCl (pH 8.0), 500 mM L-arginine, 1 mM EDTA,
5 mM reduced glutathione, 1 mM oxidized glutathione] for
50 h at 4°C. Arginine was removed by further dialysis (12 h,
4°C) against dialysis buffer [20 mM Tris (pH 8.0), 1 mM
EDTA, 10% glycerol, 50 mM NaCl] with a further change of
this buffer 12 h later. Purification by ion exchange and gel
filtration chromatography was carried out as previously
described (Koth et al., 2010). We refer to the resulting
complex as the AM1 receptor ECD. The components of the
AM1 receptor complex were digested with trypsin (Promega,
Madison, WI, USA) and then analysed by reversed-phase
LC-MS/MS on a QSTAR XL (AB Sciex, Foster City, CA, USA).
Matches with cloned sequences were identified using Mascot
v2.0.05 software (Matrix Science, London, UK) and by
manual interpretation of some spectra representing modified
sequences. Peptide peak areas were integrated using the
LC-MS Reconstruct tool within Analyst QS1.1 software (AB
Sciex).
Analytical gel filtration
Analytical gel filtration was carried out using a Superdex 75
10/300 GL column (GE Healthcare, Buckinghamshire, UK)
and low MW standards (Sigma-Aldrich) of 66, 29, 12.4 and
6.5 kDa. In addition, 0.5 mL of purified AM1 receptor ECD,
CLR and MW standards were loaded onto the column as
separate runs in gel filtration buffer.
Isothermal titration calorimetry (ITC)
ITC was undertaken on a MicroCal ITC titration calorimeter
(MicroCal Inc., Northampton, MA, USA). All experiments
were carried out in duplicate. The reaction cell contained
purified AM1 receptor ECD in the gel filtration buffer [20 mM
Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 10% glycerol] at
30 mM, degassed at 1/3 atm for 10 min. AM22–52 or its ana-
logues were dissolved in the gel filtration buffer to 300 mM
and similarly degassed. The peptide was titrated into the cell
over 27 titrations of 10 mL at 400 s intervals. The experiment
was carried out at 25°C and a stirring speed of 307 r.p.m.
Heats of dilution were determined from control titrations;
peptide was injected into buffer or buffer injected into AM1
receptor under the same conditions. The heat generated per
injection was obtained by numerical integration of the raw
data. Heats of dilution were subtracted from the observed
heats of binding before model fitting and parameter calcula-
tion. A one set of sites binding model was used, from which
the dissociation constant (Kd), the enthalpy and entropy of
binding (H and S, respectively) and the binding stoichiom-
etry were calculated.
CD spectroscopy
CD measurements were carried out as previously described
(Robinson et al., 2009) using a p-Star 180 spectrometer
(Applied Photophysics, Leatherhead, UK). CD spectra for
AM22–52 or its analogues in 50% trifluoroethanol (TFE) at
50 mM were collected from 260 to 180 nm at 1 nm intervals
with a bandwidth of 1 nm and a data collection time of 1 s at
each wavelength under nitrogen gas. An average of five
spectra was taken and baseline data for 50% TFE alone were
subtracted to give absolute CD values. Molar ellipticity values
for these spectra were calculated and analysed for secondary
structure content using the K2D program (Andrade et al.,
1993).
NMR sample preparation
NMR samples contained 0.6 mM isotope-labelled 13C/15N
AM22–52 or 0.4 mM isotope-labelled 13C/15N AM22–52 in a 1:2
ratio with the AM1 receptor ECD. NMR samples were prepared
in 20 mM Tris–HCl (pH 6.1), 1 mM EDTA, 150 mM NaCl and
93/7% (v/v) H2O/D2O.
NMR spectroscopy and data processing
NMR experiments were performed at 298 K using a Bruker
AV600 spectrometer (Bruker Corporation, Rheinstetten,
Germany) equipped with a 5-mm z-gradient 1H/15N/13C cryo-
probe optimized for 1H detection. All experiments were per-
formed with the 1H carrier positioned on the 1H2O resonance
and the 15N carrier at 117.1 p.p.m.
Two-dimensional (2D) 1H-15N HSQC experiments were
recorded using conventional watergate and water flip-back
methods (Grzesiek and Bax, 1993). The data matrix consisted
of 128* ¥ 1024* data points (where n* refers to complex
points) with acquisition times of 72.6 (tN) and 136.4 ms (tHN).
The recycle delay was 1.1 s, with eight transients per incre-
ment. The total experimental time was 20 min. 15N decou-
pling was applied during data acquisition. 13C decoupling was
achieved using an adiabatic pulse placed in the centre of the
tN period. Proton chemical shifts were referenced to TSP,
whereas the 15N and 13C chemical shifts were indirectly refer-
enced according to the ratios given by Wishart et al. (1995).
The triple resonance three-dimensional (3D) spectra
[CBCANH, CBCA(CO)NH, HNCA] were recorded as constant-
time water flip-back experiments (Grzesiek and Bax, 1992a,b;
1993). The CBCANH and CBCA(CO)NH data matrices con-
sisted of 70*(t1) ¥ 37*(t2) ¥ 1024*(t3) data points, with acqui-
sition times of 6.6, 21.7 and 136.4 ms respectively. The total
acquisition time for each experiment was 16 h. The 3D HNCA
data matrix consisted of 55*(t1) ¥ 35*(t2) ¥ 1024*(t3) data
points, with acquisition times of 11.4, 19.8 and 136.4 ms
respectively. The total acquisition time was 48 h. The 13C
carrier was positioned at 53 p.p.m. in the 3D experiments.
Datasets were processed using NMRPipe (Delaglio et al., 1995)
and analysed with CcpNmr analysis (Vranken et al., 2005).
Chemical shift perturbation
For analysis of the backbone 1HN and 15N chemical shift per-
turbations, a weighed average chemical shift change was cal-
culated using the following equation (Grzesiek et al., 1996):
Δ
Δ Δ
ave
NH
N
=
+δ δ2
2
25
2
where DdNH is the proton chemical shift change and DdN is the
15N chemical shift change.
Results
Isolation of the AM1 receptor ECD
Co-refolding of CLR (23–133) and RAMP2 (36–144) into
500 mM arginine from 8 M urea proceeded with no precipi-
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tate visible after 50 h of dialysis; a small amount of precipi-
tation occurred upon removal of arginine by dialysis into the
dialysis buffer. This may have been due to impurities in the
inclusion body preparations. Anion exchange and gel filtra-
tion chromatography yielded a stable receptor ECD complex
that co-eluted as a single peak after both chromatography
processes (Figure 1A). Functional folding and complex forma-
tion of the AM1 receptor ECD was confirmed by ITC, which
gave a Kd of 5 mM for AM22–52 (Figure 1B). The data also con-
firmed the presence of a single AM1 receptor binding site for
the AM22–52 peptide. Analytical gel filtration of the AM1 recep-
tor ECD at a concentration of 0.5 mg·mL-1 revealed a single
peak eluting at a volume corresponding to a MW of 46.5 kDa.
The expected MW of the AM1 receptor heterodimer is
29.4 kDa, composed of the 16.3 kDa RAMP2 and 13.1 kDa
CLR molecules (Figure 1C). Protein complex digestion and
LC-MS/MS followed by searching against the predicted frag-
ments for CLR and RAMP2 using the Mascot software yielded
a positive identification for the peptides. Peak integration of
the LC-MS/MS data of the peptide fragments revealed a 1.5:1
ratio of CLR to RAMP2 (Figure 1C). This indicates the pres-
ence of a CLR homodimer and a RAMP2 monomer in the
AM1 receptor complex. A complex with this stoichiometry
would have an expected MW of 42.5 kDa. This corresponds
to a MW of 46.5 kDa observed by analytical gel filtration
chromatography.
Identification of the AM1 receptor epitope
of AM22–52
We undertook solution-state NMR studies on 13C/15N AM22–52
to identify key residues located at the binding interface
between the AM1 receptor ECD and the peptide. The 2D
1H-15N HSQC spectrum of apo-AM22–52 is presented in
Figure 2A. The sequence-specific 1H-15N assignments of apo-
AM22–52 were derived from 3D CBCANH and CBCA(CO)NH
experiments, and resonances are labelled with assignment
information. Chemical shift indexing with the 1HN, 1Ha, 13Ca
and 13Cb chemical shifts indicated that there was no apparent
secondary structure present in the apo-form of AM22–52 (Sup-
porting Information Figure S1, Table S2). However, a distinct
linear epitope was evident at the C terminus of the peptide
(Supporting Information Figure S1). The uniform incorpora-
tion of 13C and 15N into the synthetic AM22–52 peptide facili-
tated backbone resonance assignment of AM22–52 in complex
with the AM1 receptor ECD (Figure 2A). To achieve backbone
resonance assignment of the peptide complex with the recep-
tor, a 3D HNCA spectrum was used in conjunction with
the available assignment information of the apo-peptide.
Although all backbone 1HN and 15N resonances were assigned
for AM22–52 in the free form, assignments for residues Q24, I47
and Y52 were not assigned in the peptide-receptor complex.
For these residues, resonances were either not visible or sig-
nificantly line-broadened in the 2D 1H-15N HSQC spectrum,
indicative of chemical exchange broadening resulting from
flexibility on the microsecond to millisecond timescale. In
addition, resonances for residues Y31, Q32, F33, T34, N40,
V41, A42, R44 and G51 were weak and were only observed at
low contour levels (resonance frequencies are depicted as
dashed circles in Figure 2A). These resonances are likely to be
affected by chemical exchange, therefore leading to a reduc-
tion in signal intensity.
The 2D 1H-15N HSQC for AM22–52 in complex with the AM1
receptor ECD shows the same resonance dispersion as
observed in the spectrum of the free form (Figure 2A). Signifi-
cant differences in linewidths and chemical shift perturba-
tions were observed upon complex formation. A qualitative
analysis of the chemical shift perturbation was performed
using the normalized weighed 1HN/15N chemical shift average,
as shown in Figure 2B, for AM22–52 in its free and AM1 receptor
ECD bound form. The results indicate that resonances arising
for residues located in the C-terminal segment of the peptide
exhibit strong variations in chemical shifts between the free
form and the complex. Residues with a weighed chemical
shift perturbation (Dd) larger than 0.15 p.p.m. (average plus 1
SD) are S45 (Dd = 0.65 p.p.m.), K46 (Dd = 0.25 p.p.m.) S48
(Dd = 0.33 p.p.m.), Q50 (Dd = 0.38 p.p.m.) and G51 (Dd =
0.70 p.p.m.), with an average of 0.4620  0.0403 p.p.m.
over these residues (Figure 2B). Residues located in the
N-terminal segment (i.e. residues 24–44) showed a signifi-
cantly smaller average chemical shift perturbation (0.0170 
0.0004 p.p.m.), indicating that these residues are not at the
key binding interface and the small changes reflect subtle
conformational rearrangements being transmitted through
the peptide to facilitate binding to the receptor. Unfortu-
nately, due to missing assignment information, chemical
shift perturbations could not be obtained for residues Q24,
I47 and Y52. The chemical shift mapping results clearly indi-
cate that the C-terminal segment of AM22–52 is a major AM1
receptor ECD binding epitope.
Alanine substitution of AM22–52
residues 44–52
To investigate and characterize the roles of the individual
amino acids constituting this major AM1 receptor ECD
binding epitope of AM22–52, each residue in this region was
individually replaced with alanine. Two complementary
methods were used to determine the impact of these substi-
tutions: binding affinities of these peptides were determined
by ITC at the AM1 receptor ECD and in functional assays at
the full-length AM1, AM2 and CGRP receptors.
All ITC experiments were carried out at a concentration of
30 mM AM1 receptor ECD, with a 10-fold excess of peptide.
The measurements for each peptide were carried out in dupli-
cate using a different preparation of AM1 receptor ECD for
each experiment. Y52A, G51A and I47A AM22–52 completely
abolished binding to the AM1 receptor ECD (Table 1), indi-
cating that these residues are intrinsically involved in AM22–52
binding to the AM1 receptor. K46A AM22–52 resulted in a
10-fold decrease in binding affinity. Small changes in binding
affinity were seen for Q50A, P49A, S48A and R44A AM22–52.
The chemical shift changes seen in the NMR HSQC experi-
ments for these residues may be due to a change in their
molecular environment because of their increased proximity
to the AM1 receptor ECD. This change in environment could
also be due to a structural change within the peptide occur-
ring upon its binding to the receptor.
The binding affinity of AM22–52 at 37°C was determined in
the same manner as that measured at 25°C and showed a
decrease in binding affinity to 29 mM. The enthalpy change
became more negative at -31.4 kcal·mol-1 when the experi-
ment was conducted at 37°C, indicating that the AM22–52-AM1
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receptor ECD interaction is predominantly through hydro-
phobic interactions.
Affinities of alanine-substituted peptides were also deter-
mined at the full-length AM1 receptor transfected into Cos-7
cells. AM22–52 behaves as an antagonist of AM-stimulated
cAMP production. The ability of each peptide to antagonize
the receptor was compared to AM22–52 (Table 2). Y52A, G51A
and I47A AM22–52 resulted in 100-fold reduction in antago-
nist potency compared to AM22–52. R44A, K46A, S48A and
P49A AM22–52 decreased antagonist potency by approximately
10-fold, whereas S45A and Q50A AM22–52 showed no signifi-
cant alteration (Figure 3). A peptide comprising only the
C-terminal 9 amino acids (9-mer) had no detectable affinity.
AM and thus its AM22–52 fragment can also bind to the
CGRP and AM2 receptors. To determine if these same residues
are also important for binding in the presence of a different
RAMP, Cos-7 cells were transfected with CLR and RAMP1
(CGRP receptor) or CLR and RAMP3 (AM2 receptor). Similar
patterns were observed for most peptides at both receptors
(Table 2). P49A AM22–52 did not, however, lose affinity at the
CGRP receptor and R44A AM22–52 only lost affinity at the AM1
receptor.
CD spectroscopy of AM22–52 and its
alanine analogues
CD was carried out on AM22–52, its analogues and the isolated
C-terminus in order to establish that any functional change
observed was not due to a change in the intrinsic structure of
the peptide upon modification. No significant change in the
relative proportions of a-helix or b-sheet was observed upon
the introduction of the alanine substitutions (Table 3). On
the other hand, the 9-mer had no secondary structure in 50%
TFE.
Discussion
The ECD of the AM1 receptor was successfully refolded and
purified from its constituent RAMP2 and CLR ECDs. Analyti-
cal gel filtration yielded a MW of 46.5 kDa for the purified
receptor ECD. Together with the MS data, this value indicates
a stoichiometry of two CLR molecules to one RAMP2 mol-
ecule. When refolded and purified in the absence of the
RAMP2 molecule, the CLR ECD shows obvious oligomeriza-
tion with elution peaks corresponding to a single CLR at 13.3
and a multimer at 69.8 kDa. Recent crystal structures of the
CGRP and AM1 receptor (ter Haar et al., 2010; Kusano et al.,
2012) indicate that the ECD of these receptor complexes
exhibit a 1:1 stoichiometry of their CLR : RAMP compo-
nents. These structures were solved using shortened frag-
ments of both CLR and RAMP1 or 2 of varying length,
selected for by their propensity to crystallize. Indeed, the
AM1 receptor structure used a RAMP2 fragment significantly
Figure 1
(A) SDS-PAGE analysis from refolding and purification of RAMP236–144 and CLR23–133 inclusion bodies to generate pure AM1 receptor ECD for NMR
analysis and biophysical studies. (i) Purified CLR and RAMP2 inclusion bodies in 8 M urea, 0.1 M Tris–HCl (pH 8.0). (ii) Ion-exchange chroma-
tography trace monitoring absorbance at 280 nm and SDS-PAGE analysis of ion exchange chromatography of refolded AM1 receptor ECD
complex. The contents of each lane on the SDS-PAGE gel contain protein from the corresponding eluted fractions illustrated on the trace above.
Lane 1 shows co-refolded receptor components. Fractions in lanes 2–5 contain mainly RAMP2 alone and some impurities. Lanes 6–9 contain an
approximate 1:1 complex of RAMP236–144 and CLR23–133 forming the AM1 receptor; these were pooled and loaded onto a gel filtration column. (iii)
Gel filtration chromatography trace monitoring absorbance at 280 nm and SDS-PAGE analysis of the AM1 receptor ECD complex. Fractions in lanes
8–13 contain RAMP236–144 and CLR23–133 in an approximate 1:1 complex which constitutes the pure AM1 receptor ECD. These fractions were pooled
and concentrated to 30 mM and used in isothermal titration calorimetry (ITC). Fractions in lanes 2–7 contain possible higher MW aggregates of
the receptor complex. Lane 1 contains the crude AM1 receptor complex from ion exchange chromatography. (B) ITC showing the (i) raw binding
data for progressive 10 mL injections of AM22–52 at 300 mM and (ii) peak integration of heats of binding. (C) Analytical gel filtration was used to
confirm the size of the AM1 receptor complex. (i) Calibration curve based on the elution volumes of four MW standards, 66, 29, 12.4 and 6.5 kDa;
this was used to calculate the molecular weights corresponding to the elution peaks of the AM1 receptor and CLR. (ii) Gel filtration chromatogram
of CLR alone, a peak at 13.3 and 69.8 kDa corresponding to the monomer and a possible 5-mer aggregate were seen. (iii) Gel filtration
chromatogram of the purified AM1 receptor showing a peak at 46.5 kDa; this may correspond to a stoichiometric complex of two CLR and one
RAMP2 molecule. (iv) Graph showing the summed peak areas obtained by LC-MS/MS per micromole of each protein in the digested complex.
This shows a 1.5:1 CLR : RAMP2 ratio in the AM1 receptor complex.

Table 1
Isothermal titration calorimetry for AM22–52 and alanine analogues of
the C-terminal nine residues of AM22–52 at the AM1 receptor ECD
Peptide Kd (mM)
H
(kcal·mol-1)
S
(cal·K-1·mol-1)
AM22–52 5.00 -13.62 -21.7
Y52A AM22–52 No binding – –
G51A AM22–52 No binding – –
Q50A AM22–52 7.35 -10.4 -11.4
P49A AM22–52 12.1 -7.53 -2.73
S48A AM22–52 8.9 -115 -15.6
I47A AM22–52 No binding – –
K46A AM22–52 51.5 – –
S45A AM22–52 5.3 -23 -52.8
R44A AM22–52 14.9 -18.2 -38.9
Values shown are the mean of two values (n = 2); in no case does
the error exceed 17% of the value indicated. No binding indi-
cates that no value was measurable due to the low affinity of the
peptide-receptor interaction. – denotes an immeasurable value
due to the low affinity binding and thus inaccuracy of these
measurements.
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shorter than that used in this study. This may have selected
for fragments which form a 1:1 stoichiometric complex. The
asymmetric unit of the AM1 receptor contains a dimer of the
heterodimer AM1 receptor complex in which hydrogen
bonding has been observed between the two CLR molecules.
It may be the case that the 46.5 kDa MW observed in ana-
lytical gel filtration in this study corresponds to a dimer of
the AM1 receptor heterodimer, as seen in the AM1 receptor
structure (Kusano et al., 2012), although this would seem
unlikely given the ratio of approximately 1.5:1 CLR : RAMP2
observed by MS. This non-integer ratio is most likely due to
a lower molar response on average for the population of
peptides representing one protein over the other; however, it
nevertheless indicates a significantly higher proportion of
CLR, and taken together with the apparent MW of the
complex as observed by analytical gel filtration, supports a
2:1 stoichiometric ratio of CLR : RAMP2 over any other
hypothesis. It is worth considering that in both crystal struc-
tures and this study, the ECD is not in its full-length physi-
ological form and thus not subject to spatial constraints that
would be present in the full-length receptors. Investigations
on the oligomerization of the full-length CGRP receptor
report a stoichiometry of a CLR homo-oligomer and a
RAMP1 monomer, consistent with our observations for CLR
and RAMP2 (Heroux et al., 2007).
Irrespective of the actual stoichiometry, the purified AM1
receptor ECD was capable of binding AM22–52 with a Kd of
5 mM. Binding studies of various peptide fragments to their
receptors have been carried out using both ITC and surface
plasmon resonance (Parthier et al., 2007; Pioszak and Xu,
2008; Koth et al., 2010; Drechsler et al., 2011; Kusano et al.,
2012). Depending on the receptor and the methodology
used, the binding affinities of these peptide fragments to their
receptor ECDs vary across the milli- to nanomolar ranges but
are predominantly in the low micromolar range. Therefore,
the Kd we observed for AM22–52 is in-line with expectations
from this literature. In the two-domain model of peptide
ligand binding to this class of GPCR (Parthier et al., 2009),
the peptide C-terminus binds to the ECD and the peptide
N-terminus binds to the receptor transmembrane bundle and
extracellular loops. Thus, the affinities determined by ITC are
likely to be lower when not all points of contact with the
receptor are available for that particular peptide. For AM22–52,
the lower affinity at the ECD in ITC compared with the
full-length receptor in the cAMP assay could suggest that
AM22–52 may be making contact with parts of the receptor
other than the ECD. However, differences in these assays
make it difficult to directly compare values. It would be inter-
esting to compare the affinities of different lengths of AM
between the two assays.
In solution-state NMR studies, we were able to assign
backbone resonances for both the apo and receptor bound
forms of AM22–52. Only a small number of resonances under-
went large chemical shift changes when AM22–52 was mixed
with the AM1 receptor ECD. Nonetheless, we observed signifi-
cant differences in both linewidths and chemical shift per-
turbations for a number of residues upon complex formation.
Resonances arising from G51, Q50, S48, K46 and S45 showed
a weighed chemical shift perturbation greater than the
average plus 1 SD (0.15 p.p.m.), which was significantly larger
than those observed for the remainder of the molecule.
Assignments for I47, Y52 and Q24 were not made. These
omissions notwithstanding, we can clearly locate the major
AM1 receptor ECD binding epitope of AM22–52 to the last eight
residues at the C-terminus of the peptide.
Figure 2
(A) 2D 1H-15N HSQC spectra of AM22–52 in the free-state (black)
overlaid with AM22–52 bound to the AM1 receptor ECD (red). Dashed
circles depict resonances that were too low to be observed at the
contour level plotted for the HSQC of AM22–52 bound to the AM1
receptor. Residues S45, K46, S48, Q50 and G51 undergo large
chemical shift perturbations. The changes in chemical shift for these
resonances are indicated by black dotted lines that link the corre-
sponding signals assigned in the free and bound states. (B) Weighted
1HN, 15N average chemical shifts between AM22–52 in the free and
bound form with the AM1 receptor ECD. The average over all resi-
dues plus 1 SD is depicted by the black line. No assignments were
obtained for residues Q24, I47 and Y52 in the complex. Additionally,
there are two prolines (P43, P49) in the AM22–52 sequence.
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Guided by these NMR results and previous studies by
Robinson et al. (2009), which implicated these amino acids of
AM22–52 in binding to the AM2 receptor, we made progressive
alanine substitutions of the C-terminal amino acid residues of
AM22–52. Characterization of these peptides in ITC and func-
tional assays further pin-pointed residues Y52, G51, I47 and
K46 as essential for high-affinity receptor interactions. Each
of these substitutions resulted in substantial reductions in
binding affinity to the AM1 receptor ECD and full-length
receptor. CD spectroscopy indicated that there was no major
structural perturbation to these peptides. This allows us to
infer that these residues are present at the AM1 receptor
binding interface and may be forming discrete interactions
with the receptor ECD. Previous structure–activity studies
have shown that both Y52 and the C-terminal amide group
characteristic of many class B GPCR peptide ligands are essen-
tial for AM binding to its full-length receptor, although they
appear to have discrete roles in this process (Eguchi et al.,
1994).
The chemical shift perturbations observed for the remain-
ing residues in the C-terminal binding epitope determined by
NMR (e.g. S45, Q50) may be due to the proximity of these
residues to the binding cleft or a change in peptide structure
as it binds to the receptor ECD. Thermodynamic data can
give us no information on the exact nature or number of
these potential interactions. The increase in negativity of the
Table 2
pA2 values of antagonist potency for AM22–52 and alanine analogues of the C-terminal amino acids at full-length receptors, generated in cAMP
assays
Peptide AM1 receptor AM2 receptor CGRP receptor
AM22–52 7.83  0.19 (n = 6) 7.38  0.10 (n = 6) 5.77  0.23 (n = 6)
13C/15N AM22–52 7.88  0.14 (n = 3) ND ND
Y52A AM22–52 <4 (n = 3)a <4 (n = 3) <4 (n = 3)
G51A AM22–52 <4 (n = 3)b <4 (n = 4) <4 (n = 3)
Q50A AM22–52 7.45  0.23 (n = 4) 6.88  0.09* (n = 5) 5.81  0.29 (n = 3)c
P49A AM22–52 6.74  0.10*** (n = 3) 6.53  0.14*** (n = 5) 5.32  0.21 (n = 3)d
S48A AM22–52 7.03  0.10** (n = 4) 6.10  0.11*** (n = 4) <5 (n = 4)
I47A AM22–52 5.84  0.22*** (n = 3)c <5 (n = 3) <5 (n = 3)
K46A AM22–52 6.39  0.17*** (n = 3) 5.96  0.11*** (n = 3) <5 (n = 3)
S45A AM22–52 8.39  0.09 (n = 4) 7.31  0.21 (n = 4) 5.59  0.20 (n = 5)
R44A AM22–52 6.89  0.07** (n = 3) 7.37  0.18 (n = 4) 5.64  0.18 (n = 4)
9-mer <4.30 (n = 3) <4.30 (n = 3) <4.30 (n = 3)
Error is presented as the SEM. *P < 0.05; **P < 0.01; ***P < 0.001 versus AM22–52 by one-way ANOVA, followed by Dunnett’s multiple
comparison test.
aPeptide gave significant shifts in two further experiments with pA2 values of 5.28 and 5.67 respectively.
bPeptide gave significant shifts in two further experiments with pA2 values of 4.55 and 5.32 respectively.
cPeptide did not produce a measurable shift in the AM concentration–response curve in a further two experiments; therefore, pA2 values could
not be determined for those occasions.
dPeptide did not produce a measurable shift in the AM concentration–response curve in a further experiment; therefore, a pA2 value could
not be determined for that occasion.
ND, not done.
Table 3
Relative percentages of secondary structural elements for AM22–52 and alanine substitutions of the C-terminal nine amino acids as determined by
circular dichroism spectroscopy
AM22–52
Y52A
AM22–52
G51A
AM22–52
Q50A
AM22–52
P49A
AM22–52
S48A
AM22–52
I47A
AM22–52
K46A
AM22–52
S45A
AM22–52
R44A
AM22–52 9-mer
a-Helix 26 28 26 23 27 26 22 28 25 27 7
b-Sheet 27 30 26 23 17 26 22 30 20 28 51
Random coil 46 42 47 53 56 47 56 42 55 45 42
Circular dichroism data were deconvoluted using the online web server K2D. These values should be used with caution; analysis using
different programmes yields varying percentages and, therefore, these values are only useful for comparing between peptides and not
necessarily between studies.
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Figure 3
Concentration–response curves for the alanine mutants of AM22–52 at the AM1 receptor. Cos-7 cells were transfected with HA tagged CLR and
untagged RAMP2 and assayed for human AM-stimulated cAMP response. Curves are plotted as a percentage of the maximal human
AM-stimulated cAMP production. Each figure shows combined data from three to five independent experiments, which were each performed in
triplicate. Each point on the graphs represents the mean  SEM. Due to the different affinities of the peptides, different concentrations were used,
up to the possible maximum for that peptide in order to obtain shifts.
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DH values at 37°C compared with those at 25°C does,
however, indicate that the binding interactions are of a
mainly hydrophobic nature. This would be consistent with
the accepted mode of binding of peptides to other class B
GPCRs (Parthier et al., 2009).
At the AM2 receptor, the same residues appear to have a
significant involvement in functional antagonist activity as
we observed at the AM1 receptor. Antagonist activities at the
CGRP receptor were very low, meaning that any decrease in
these due to the effect of alanine substitutions resulted in a
complete abolition of antagonist activity detectable by our
system. R44A AM22–52 showed a selective decrease in affinity at
the AM1 receptor and also showed a threefold decrease in Kd
at the AM1 receptor ECD as determined by ITC. This may be
a RAMP2-dependent residue. When it becomes possible to
solve peptide bound structures of the AM1 and AM2 receptors,
it will be interesting to see what contribution this residue
makes to binding. Surprisingly, R44 did not show a substan-
tial chemical shift perturbation when the peptide was mixed
with the receptor. The reason for this discrepancy is unclear.
Interestingly, the 9-mer fragment comprising only the last
nine amino acids of AM22–52 had no measurable affinity. On
the other hand, it appears unstructured in CD analysis and
this may explain its lack of activity. Other portions of the
peptide may be required to stabilize the conformation of this
region needed for binding. Indeed, we observed small chemi-
cal shifts for the residues Q24-T34 of AM22–52, indicating that
these also have a functional role to play in the peptide (Eguchi
et al., 1994; Robinson et al., 2009). Future studies could seek to
stabilize C-terminal fragments of varying length, based on our
observations of the importance of this region.
Although many crystal structures of class B GPCRs are
now available, most have only short peptide fragments
bound and few encompass the extreme C-terminus. The
recent structure of the AM1 receptor ECD does not have
peptide bound, although it does indicate some residues in the
receptor that may be involved in AM binding (Kusano et al.,
2012). Existing NMR structures of AM (Perez-Castells et al.,
2012) and AM22–52 (Supporting Information Figure S2) are not
suitable for docking into the receptor crystal structure. Those
other class B GPCR structures that do include the C-terminal
region of peptide fragments indicate that peptide residues
involved in receptor binding are situated towards the middle
of the peptide rather than at the extreme C-terminus
(Parthier et al., 2007; Underwood et al., 2010a,b). However,
alanine scanning has implicated residues closer to the
C-terminus of other class B peptide ligands in receptor
binding (Lang et al., 2006; Grace et al., 2007; Pioszak and Xu,
2008; Dong et al., 2011). In particular, amino acid substitu-
tions within a C-terminal 10-mer of CGRP showed antagonist
activity in the nanomolar range (Rist et al., 1998). Substitu-
tion, the enhancement of b-turns and cyclization by disul-
phide bond formation of this 10-mer peptide resulted in
antagonists with even higher picomolar affinity for the CGRP
receptor (Lang et al., 2006; Yan et al., 2011). Therefore, the
importance of the extreme peptide C-terminus may be a
particular feature of the AM and CGRP receptors. This may
correlate with the requirement for RAMPs in high affinity
binding; the recent structure would certainly indicate a shift
in binding pocket if RAMP2 is directly involved in AM
binding (Kusano et al., 2012).
In this study, we have pin-pointed a discrete AM22–52
epitope between residues R44 and Y52, which is involved in
binding to the AM1 receptor. We have defined the precise
residues of AM22–52, which are involved in binding to the AM1
receptor and the role that they play within the binding
epitope. This complements structural studies of the receptor,
although more constraints are required to allow accurate
docking of AM into the receptor. Our study provides useful
information with which to pursue the development of high
affinity antagonist analogues of AM22–52.
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Figure S1 Stereo view representation of the 15 lowest energy
solution structures of the AM22–52 peptide. The amino termi-
nus is show in dark blue, whereas the carboxy terminus is on
the opposite side and shown in brown/green.
Figure S2 Overview of AM structures for residues 22–52
in solution (left) and in the presence of SDS micelles
(right). Residues with elevated values from the chemical
shift mapping are coloured in red (S45, K46, S48, Q50,
G51).
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lowest energy structures of AM22–52.
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